Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00538304 · ClinicalTrials.gov registry record · Phase 2

A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

A Phase 2 study, sponsored by Allergan.

Completed
Registry status
Phase 2
Development phase
222
Enrollment target

NCT00538304: Completed Phase 2 study, sponsored by Allergan.

NCT00538304 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 222 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00538304, a Phase 2 study, has completed, sponsored by Allergan.

COMPLETED
Registry status
Phase 2
Development phase
222 participants
Enrollment target

Study Summary

A one month study which will determine the safety and efficacy of bimatoprost eye drops in patients with glaucoma or ocular hypertension

Primary Outcome

Change from Baseline in macroscopic conjunctival hyperemia (or visible eye redness). Macroscopic conjunctival hyperemia is graded by the investigator who compares the patient's visual appearance of eye redness to standard photographs using a 5-point scale (Scale 0 to +3: none, trace, mild, moderate, severe). The peak change is calculated for each eye by subtracting the largest score across the hourly measurements at baseline from the largest score across the hourly measurements at month 1. A pos

Interventions

  • DRUG placebo
  • DRUG bimatoprost eye drops

Trial Details

FieldValue
Enrollment Target 222 participants
Start Date 2007-11
Est. Completion 2008-05
Phase Phase 2
Allergan

314 total trials

What the finished NCT00538304 record still lists

NCT00538304 is an interventional study that assigns participants to a tested intervention. The registered 222 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% higher).

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT00538304 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00538304 about?

NCT00538304 is a clinical study titled "A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension". A one month study which will determine the safety and efficacy of bimatoprost eye drops in patients with glaucoma or ocular hypertension

What is the current status of trial NCT00538304?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2007-11. Estimated completion is 2008-05.

What interventions are being tested in trial NCT00538304?

The interventions under investigation include: placebo (DRUG), bimatoprost eye drops (DRUG).

Who is sponsoring clinical trial NCT00538304?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00538304's enrollment target sits among peer trials

222 274th of 2000 higher than 1,726 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04939610 · 222 participants · Phase 1

    A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

  • NCT05424783 · 222 participants

    MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

  • NCT05568264 · 222 participants · NA

    Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit

  • NCT05605574 · 222 participants · NA

    Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00538304, the US trial registry maintained by the National Library of Medicine. NCT00538304 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.